symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
RNXT,1.11,0.26761,30710,11869341,0,0.91-5.745,-0.02,"RenovoRx, Inc.",USD,0001574094,US75989R1077,75989R107,NASDAQ Capital Market,NASDAQ,Biotechnology,https://renovorx.com,"RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.",Mr. Shaun R. Bagai,Healthcare,US,10,650 284 4433,4546 El Camino Real,Los Altos,CA,94022,,0,https://financialmodelingprep.com/image-stock/RNXT.png,2021-08-26,False,False,True,False,False
